Mammalian gene silencing is established through methylation of histones and DNA, although the order in which these modifications occur remains contentious. Using the human β-globin locus as a model, ...

A potential target for experimental drugs that block PRMT5 - a naturally occurring enzyme some tumors rely more on for survival - has been identified by researchers with the Fralin Biomedical Research ...

Scientists at Sanford Burnham Prebys Medical Discovery Institute have demonstrated the therapeutic potential of PRMT5 inhibitors to sensitize unresponsive melanoma to immune checkpoint therapy. PRMT5 ...

Northwestern Medicine scientists have identified a key driver of chemotherapy resistance in advanced ovarian cancer, according to a study published in the Journal of Clinical Investigation. Ovarian ...

Dublin, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The "Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024" report has been added to ResearchAndMarkets.com's offering. PRMT5, or ...

Blocking an enzyme called PRMT5 in tumor cells could be a promising new strategy for the treatment of glioblastoma, the most aggressive and lethal form of brain cancer, a new study suggests. A new ...

BOSTON, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of ...

Researchers at the Advanced Science Research Center (ASRC) at The Graduate Center of The City University of New York report that they have discovered the role of a protein known as PRMT5 in the ...

SAN DIEGO, April 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced initial preclinical results evaluating its investigational ...

Bayer BAYRY announced a licensing agreement with Suzhou Puhe BioPharma Co., a clinical-stage biotechnology company. Suzhou Puhe BioPharma is focused on the research and development of innovative small ...